Advanced

Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy.

Juliusson, Gunnar LU and Samuelsson, Henrik (2011) In Leukemia & lymphoma 52 Suppl 2. p.46-49
Abstract
Hairy cell leukemia is often reported as a disease of young males. The male predominance is strong, 4:1, but the median age in the Swedish national compulsory cancer registry is similar to that of follicular lymphoma, i.e. 62 years. The overall 6-year survival in the Swedish registry of patients diagnosed since 2000 is 80%, 93% of patients <60 years, and 68% of those >60 years. The yearly risk of secondary cancers is 1.75%. Cladribine is a prodrug which is selectively activated intracellularly. The intracellular initial half-life is 13 h and the terminal half-life is 30 h. Subcutaneous injection once daily is simple and effective due to 100% bioavailability and no local side effects from injection, and self-administration is easy.... (More)
Hairy cell leukemia is often reported as a disease of young males. The male predominance is strong, 4:1, but the median age in the Swedish national compulsory cancer registry is similar to that of follicular lymphoma, i.e. 62 years. The overall 6-year survival in the Swedish registry of patients diagnosed since 2000 is 80%, 93% of patients <60 years, and 68% of those >60 years. The yearly risk of secondary cancers is 1.75%. Cladribine is a prodrug which is selectively activated intracellularly. The intracellular initial half-life is 13 h and the terminal half-life is 30 h. Subcutaneous injection once daily is simple and effective due to 100% bioavailability and no local side effects from injection, and self-administration is easy. Long-term follow-up of Scandinavian patients treated with cladribine (mostly as subcutaneous injections) in the early 1990s shows a >80% 15-year survival from cladribine treatment in <60 years of age, but <50% in older patients. Survival from diagnosis of these patients was similar for those previously treated and untreated. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Leukemia & lymphoma
volume
52 Suppl 2
pages
46 - 49
publisher
Taylor & Francis
external identifiers
  • WOS:000290869300012
  • PMID:21599605
  • Scopus:79957492280
ISSN
1029-2403
DOI
10.3109/10428194.2011.565842
language
English
LU publication?
yes
id
85e7b455-bc4c-4e46-98c1-04551335948e (old id 1972197)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21599605?dopt=Abstract
date added to LUP
2011-06-07 22:23:57
date last changed
2017-01-01 07:51:41
@article{85e7b455-bc4c-4e46-98c1-04551335948e,
  abstract     = {Hairy cell leukemia is often reported as a disease of young males. The male predominance is strong, 4:1, but the median age in the Swedish national compulsory cancer registry is similar to that of follicular lymphoma, i.e. 62 years. The overall 6-year survival in the Swedish registry of patients diagnosed since 2000 is 80%, 93% of patients &lt;60 years, and 68% of those &gt;60 years. The yearly risk of secondary cancers is 1.75%. Cladribine is a prodrug which is selectively activated intracellularly. The intracellular initial half-life is 13 h and the terminal half-life is 30 h. Subcutaneous injection once daily is simple and effective due to 100% bioavailability and no local side effects from injection, and self-administration is easy. Long-term follow-up of Scandinavian patients treated with cladribine (mostly as subcutaneous injections) in the early 1990s shows a &gt;80% 15-year survival from cladribine treatment in &lt;60 years of age, but &lt;50% in older patients. Survival from diagnosis of these patients was similar for those previously treated and untreated.},
  author       = {Juliusson, Gunnar and Samuelsson, Henrik},
  issn         = {1029-2403},
  language     = {eng},
  pages        = {46--49},
  publisher    = {Taylor & Francis},
  series       = {Leukemia & lymphoma},
  title        = {Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy.},
  url          = {http://dx.doi.org/10.3109/10428194.2011.565842},
  volume       = {52 Suppl 2},
  year         = {2011},
}